News Releases

Nuvalent to Participate in Upcoming September Investor Conferences

CAMBRIDGE, Mass., Aug. 31, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, and Alexandra Balcom, Chief Financial Officer, will participate in fireside chats during the following September investor conferences:

  • 2023 Wells Fargo Securities Healthcare Conference on Friday, September 8, 2023 at 10:15 a.m. ET in Boston;
  • Morgan Stanley 21st Annual Global Healthcare Conference on Wednesday, September 13, 2023 at 8:50 a.m. ET in NYC.

Live webcasts will be available in the investor section of the company's website at, and archived for 30 days following the presentations.

About Nuvalent
Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive non-small cell lung cancer (NSCLC), a program in HER2 Exon 20 insertion-positive cancers, and multiple discovery-stage research programs. We routinely post information that may be important to investors on our website at Follow us on Twitter (@nuvalent) and LinkedIn.


SOURCE Nuvalent, Inc.


Investor Contact:
Chelcie Lister
THRUST Strategic Communications

Media Contact:
Amanda Sellers
Verge Scientific Communications